# A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

> **NCT01888445** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 130 (actual)

## Conditions studied

- Renal Anemia Associated With Chronic Renal Failure (CRF)

## Interventions

- **DRUG:** roxadustat
- **DRUG:** darbepoetin alfa

## Key facts

- **NCT ID:** NCT01888445
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-28
- **Primary completion:** 2014-09-15
- **Final completion:** 2014-09-15
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01888445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01888445, "A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01888445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*